| Mehrnoosh Tashakori, MD | |
|
500 Harvard St Se, Minneapolis, MN 55455-0363 | |
| (313) 916-2326 | |
| Not Available |
| Full Name | Mehrnoosh Tashakori |
|---|---|
| Gender | Female |
| Speciality | Pathology |
| Experience | 20 Years |
| Location | 500 Harvard St Se, Minneapolis, Minnesota |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1366838732 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZH0000X | Pathology - Hematology | 4301107624 (Michigan) | Primary |
| 390200000X | Student In An Organized Health Care Education/training Program | (* (Not Available)) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Minnesota Medical Center, Fairview | Minneapolis, MN | Hospital |
| Fairview Southdale Hospital | Edina, MN | Hospital |
| Healtheast St John's Hospital | Maplewood, MN | Hospital |
| Fairview Ridges Hospital | Burnsville, MN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Fairview Express Care | 3375645179 | 1523 |
News Archive
New research in individuals with schizotypal personalities - people characterized by odd behavior and language but who are not psychotic or schizophrenic - offers the first neurological evidence that these individuals are more creative than normal or fully schizophrenic people, and rely more heavily on the right sides of their brains than the general population to access their creativity.
BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products, today announced that its partner Auxilium Pharmaceuticals, Inc. announced that Pfizer Inc. received notification from the European Medicines Agency that the Marketing and Authorization Application (MAA) for XIAFLEX™ for the treatment of Dupuytren's disease (a debilitating disorder resulting from excessive collagen deposition that causes contractures of the fingers) has completed the validation phase successfully and that the scientific/technical review procedure commenced today.
Men who receive a "boost" of proton therapy after receiving a standard course of X-ray radiation therapy have fewer recurrences of their prostate cancer compared to men who did not receive the extra dose of proton radiation, according to a first-of-its-kind study presented November 2, 2009, at the American Society for Radiation Oncology's 51st Annual Meeting in Chicago.
Cancer Research UK scientists have for the first time identified that there are five distinct types of prostate cancer and found a way to distinguish between them, according to a landmark study published today in EBioMedicine.
A novel imaging technique that uses a synthesized form of scorpion venom to light up brain tumors has shown promise in a clinical trial. The imaging system enables neurosurgeons to better see malignant growths that often are difficult to fully eliminate.
› Verified 7 days ago
| Entity Name | University Of Minnesota Physicians |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477598118 PECOS PAC ID: 9830001189 Enrollment ID: O20031104000532 |
News Archive
New research in individuals with schizotypal personalities - people characterized by odd behavior and language but who are not psychotic or schizophrenic - offers the first neurological evidence that these individuals are more creative than normal or fully schizophrenic people, and rely more heavily on the right sides of their brains than the general population to access their creativity.
BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products, today announced that its partner Auxilium Pharmaceuticals, Inc. announced that Pfizer Inc. received notification from the European Medicines Agency that the Marketing and Authorization Application (MAA) for XIAFLEX™ for the treatment of Dupuytren's disease (a debilitating disorder resulting from excessive collagen deposition that causes contractures of the fingers) has completed the validation phase successfully and that the scientific/technical review procedure commenced today.
Men who receive a "boost" of proton therapy after receiving a standard course of X-ray radiation therapy have fewer recurrences of their prostate cancer compared to men who did not receive the extra dose of proton radiation, according to a first-of-its-kind study presented November 2, 2009, at the American Society for Radiation Oncology's 51st Annual Meeting in Chicago.
Cancer Research UK scientists have for the first time identified that there are five distinct types of prostate cancer and found a way to distinguish between them, according to a landmark study published today in EBioMedicine.
A novel imaging technique that uses a synthesized form of scorpion venom to light up brain tumors has shown promise in a clinical trial. The imaging system enables neurosurgeons to better see malignant growths that often are difficult to fully eliminate.
› Verified 7 days ago
| Entity Name | Fairview Health Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013994359 PECOS PAC ID: 1951213057 Enrollment ID: O20031105000461 |
News Archive
New research in individuals with schizotypal personalities - people characterized by odd behavior and language but who are not psychotic or schizophrenic - offers the first neurological evidence that these individuals are more creative than normal or fully schizophrenic people, and rely more heavily on the right sides of their brains than the general population to access their creativity.
BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products, today announced that its partner Auxilium Pharmaceuticals, Inc. announced that Pfizer Inc. received notification from the European Medicines Agency that the Marketing and Authorization Application (MAA) for XIAFLEX™ for the treatment of Dupuytren's disease (a debilitating disorder resulting from excessive collagen deposition that causes contractures of the fingers) has completed the validation phase successfully and that the scientific/technical review procedure commenced today.
Men who receive a "boost" of proton therapy after receiving a standard course of X-ray radiation therapy have fewer recurrences of their prostate cancer compared to men who did not receive the extra dose of proton radiation, according to a first-of-its-kind study presented November 2, 2009, at the American Society for Radiation Oncology's 51st Annual Meeting in Chicago.
Cancer Research UK scientists have for the first time identified that there are five distinct types of prostate cancer and found a way to distinguish between them, according to a landmark study published today in EBioMedicine.
A novel imaging technique that uses a synthesized form of scorpion venom to light up brain tumors has shown promise in a clinical trial. The imaging system enables neurosurgeons to better see malignant growths that often are difficult to fully eliminate.
› Verified 7 days ago
| Entity Name | Fairview Clinics |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346432218 PECOS PAC ID: 7113830142 Enrollment ID: O20031106000516 |
News Archive
New research in individuals with schizotypal personalities - people characterized by odd behavior and language but who are not psychotic or schizophrenic - offers the first neurological evidence that these individuals are more creative than normal or fully schizophrenic people, and rely more heavily on the right sides of their brains than the general population to access their creativity.
BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products, today announced that its partner Auxilium Pharmaceuticals, Inc. announced that Pfizer Inc. received notification from the European Medicines Agency that the Marketing and Authorization Application (MAA) for XIAFLEX™ for the treatment of Dupuytren's disease (a debilitating disorder resulting from excessive collagen deposition that causes contractures of the fingers) has completed the validation phase successfully and that the scientific/technical review procedure commenced today.
Men who receive a "boost" of proton therapy after receiving a standard course of X-ray radiation therapy have fewer recurrences of their prostate cancer compared to men who did not receive the extra dose of proton radiation, according to a first-of-its-kind study presented November 2, 2009, at the American Society for Radiation Oncology's 51st Annual Meeting in Chicago.
Cancer Research UK scientists have for the first time identified that there are five distinct types of prostate cancer and found a way to distinguish between them, according to a landmark study published today in EBioMedicine.
A novel imaging technique that uses a synthesized form of scorpion venom to light up brain tumors has shown promise in a clinical trial. The imaging system enables neurosurgeons to better see malignant growths that often are difficult to fully eliminate.
› Verified 7 days ago
| Entity Name | Healtheast Medical Research Institute |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639125503 PECOS PAC ID: 3971407636 Enrollment ID: O20031124000507 |
News Archive
New research in individuals with schizotypal personalities - people characterized by odd behavior and language but who are not psychotic or schizophrenic - offers the first neurological evidence that these individuals are more creative than normal or fully schizophrenic people, and rely more heavily on the right sides of their brains than the general population to access their creativity.
BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products, today announced that its partner Auxilium Pharmaceuticals, Inc. announced that Pfizer Inc. received notification from the European Medicines Agency that the Marketing and Authorization Application (MAA) for XIAFLEX™ for the treatment of Dupuytren's disease (a debilitating disorder resulting from excessive collagen deposition that causes contractures of the fingers) has completed the validation phase successfully and that the scientific/technical review procedure commenced today.
Men who receive a "boost" of proton therapy after receiving a standard course of X-ray radiation therapy have fewer recurrences of their prostate cancer compared to men who did not receive the extra dose of proton radiation, according to a first-of-its-kind study presented November 2, 2009, at the American Society for Radiation Oncology's 51st Annual Meeting in Chicago.
Cancer Research UK scientists have for the first time identified that there are five distinct types of prostate cancer and found a way to distinguish between them, according to a landmark study published today in EBioMedicine.
A novel imaging technique that uses a synthesized form of scorpion venom to light up brain tumors has shown promise in a clinical trial. The imaging system enables neurosurgeons to better see malignant growths that often are difficult to fully eliminate.
› Verified 7 days ago
| Entity Name | Fairview Express Care |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053952606 PECOS PAC ID: 3375645179 Enrollment ID: O20081028000548 |
News Archive
New research in individuals with schizotypal personalities - people characterized by odd behavior and language but who are not psychotic or schizophrenic - offers the first neurological evidence that these individuals are more creative than normal or fully schizophrenic people, and rely more heavily on the right sides of their brains than the general population to access their creativity.
BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products, today announced that its partner Auxilium Pharmaceuticals, Inc. announced that Pfizer Inc. received notification from the European Medicines Agency that the Marketing and Authorization Application (MAA) for XIAFLEX™ for the treatment of Dupuytren's disease (a debilitating disorder resulting from excessive collagen deposition that causes contractures of the fingers) has completed the validation phase successfully and that the scientific/technical review procedure commenced today.
Men who receive a "boost" of proton therapy after receiving a standard course of X-ray radiation therapy have fewer recurrences of their prostate cancer compared to men who did not receive the extra dose of proton radiation, according to a first-of-its-kind study presented November 2, 2009, at the American Society for Radiation Oncology's 51st Annual Meeting in Chicago.
Cancer Research UK scientists have for the first time identified that there are five distinct types of prostate cancer and found a way to distinguish between them, according to a landmark study published today in EBioMedicine.
A novel imaging technique that uses a synthesized form of scorpion venom to light up brain tumors has shown promise in a clinical trial. The imaging system enables neurosurgeons to better see malignant growths that often are difficult to fully eliminate.
› Verified 7 days ago
| Entity Name | University Of Minnesota Health Clinics And Surgery Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053795187 PECOS PAC ID: 9133423304 Enrollment ID: O20160209000524 |
News Archive
New research in individuals with schizotypal personalities - people characterized by odd behavior and language but who are not psychotic or schizophrenic - offers the first neurological evidence that these individuals are more creative than normal or fully schizophrenic people, and rely more heavily on the right sides of their brains than the general population to access their creativity.
BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products, today announced that its partner Auxilium Pharmaceuticals, Inc. announced that Pfizer Inc. received notification from the European Medicines Agency that the Marketing and Authorization Application (MAA) for XIAFLEX™ for the treatment of Dupuytren's disease (a debilitating disorder resulting from excessive collagen deposition that causes contractures of the fingers) has completed the validation phase successfully and that the scientific/technical review procedure commenced today.
Men who receive a "boost" of proton therapy after receiving a standard course of X-ray radiation therapy have fewer recurrences of their prostate cancer compared to men who did not receive the extra dose of proton radiation, according to a first-of-its-kind study presented November 2, 2009, at the American Society for Radiation Oncology's 51st Annual Meeting in Chicago.
Cancer Research UK scientists have for the first time identified that there are five distinct types of prostate cancer and found a way to distinguish between them, according to a landmark study published today in EBioMedicine.
A novel imaging technique that uses a synthesized form of scorpion venom to light up brain tumors has shown promise in a clinical trial. The imaging system enables neurosurgeons to better see malignant growths that often are difficult to fully eliminate.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mehrnoosh Tashakori, MD 720 Washington Ave Se Ste 300, Minneapolis, MN 55414-2904 Ph: (612) 884-0649 | Mehrnoosh Tashakori, MD 500 Harvard St Se, Minneapolis, MN 55455-0363 Ph: (313) 916-2326 |
News Archive
New research in individuals with schizotypal personalities - people characterized by odd behavior and language but who are not psychotic or schizophrenic - offers the first neurological evidence that these individuals are more creative than normal or fully schizophrenic people, and rely more heavily on the right sides of their brains than the general population to access their creativity.
BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products, today announced that its partner Auxilium Pharmaceuticals, Inc. announced that Pfizer Inc. received notification from the European Medicines Agency that the Marketing and Authorization Application (MAA) for XIAFLEX™ for the treatment of Dupuytren's disease (a debilitating disorder resulting from excessive collagen deposition that causes contractures of the fingers) has completed the validation phase successfully and that the scientific/technical review procedure commenced today.
Men who receive a "boost" of proton therapy after receiving a standard course of X-ray radiation therapy have fewer recurrences of their prostate cancer compared to men who did not receive the extra dose of proton radiation, according to a first-of-its-kind study presented November 2, 2009, at the American Society for Radiation Oncology's 51st Annual Meeting in Chicago.
Cancer Research UK scientists have for the first time identified that there are five distinct types of prostate cancer and found a way to distinguish between them, according to a landmark study published today in EBioMedicine.
A novel imaging technique that uses a synthesized form of scorpion venom to light up brain tumors has shown promise in a clinical trial. The imaging system enables neurosurgeons to better see malignant growths that often are difficult to fully eliminate.
› Verified 7 days ago
Khalid Amin, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 420 Delaware St Se, C463 Mayo Memorial Bldg, Mayo Mail Code 76, Minneapolis, MN 55455 Phone: 913-827-3505 | |
Dr. Laura L Schmitz, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 3300 Oakdale Ave N, Minneapolis, MN 55422 Phone: 763-581-4150 Fax: 763-581-4151 | |
Dr. Michael Patrick Greenwood, MD Pathology Medicare: Medicare Enrolled Practice Location: 909 Fulton St Se, Minneapolis, MN 55455 Phone: 612-672-7422 | |
Deborah Elizabeth Powell, MD Pathology Medicare: Medicare Enrolled Practice Location: 500 Harvard St Se, Lab Med & Pathology, Minneapolis, MN 55455 Phone: 612-273-1142 | |
Yiang Hui, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 2800 10th Ave S Ste 2200, Minneapolis, MN 55407 Phone: 612-767-8373 | |
Dr. Pamela Ann Sakkinen, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 2800 10th Ave S Ste 2200, Hospital Pathology Assoc, Minneapolis, MN 55407 Phone: 612-767-8370 Fax: 612-767-8376 | |
Kevin Todd Stieglbauer, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 2800 10th Ave S Ste 2200, Hospital Pathology Assoc, Minneapolis, MN 55407 Phone: 612-767-8370 Fax: 612-767-8376 |